Zota Health Care Ltd
Zota Health Care Q2 Results 2026 (FY27): Guides 40%+ Revenue Growth, Steady Margins
Q2 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹199Cr
- +54.3% YoY
- Net profit
- −₹26Cr
- Q2 FY26: −₹16 Cr
- Margin
- 1.5%
- −3.4 pp YoY
Guidance rank: #5 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Zota Health Care Ltd Q2 FY27 key numbers
- Revenue
- Mature stores show improving productivity; stores opened between FY21-FY24 have average monthly GMV of ₹4.6 lakh and growing.
As stated in Zota Health Care Ltd's Q2 FY27 earnings call transcript · published 28 Oct 2026. Reported figures, not investment advice.
The short version
Davaindia sales grew by over 76% year-on-year in Q2FY27, indicating strong underlying momentum. Mature Davaindia stores show strong growth potential with monthly GMV reaching ₹8 lakh per store and potential to go up to ₹10-15 lakh in 2-3 years.
From Zota Health Care Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Zota Health Care's revenue grow in the September 2026 quarter?
- Davaindia sales grew by over 76% year-on-year in Q2FY27, indicating strong underlying momentum.
- The store network expanded rapidly to 2,840 stores as of September 30, 2026, with plans to open 600-650 new stores in FY27 and 800 new stores in FY28, supporting further growth.
- Mature stores show improving productivity; stores opened between FY21-FY24 have average monthly GMV of ₹4.6 lakh and growing.
- Average GMV per mature store (over 54 months old) crossed ₹8 lakh per month, with a 10% quarter-on-quarter growth, indicating further upside potential.
- Quarterly GMV improved substantially; Davaindia's quarterly GMV increased to ₹188 crore in Q2FY27 vs. ₹106 crore previous year.
2 more points from Zota Health Care Ltd's call on revenue
Create a free account to keep reading this call
What happened to Zota Health Care's margins in Q2 FY27?
See what Zota Health Care Ltd said on profitability & margins — free account, 30 seconds.
What capex is Zota Health Care planning?
2 more points from Zota Health Care Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Zota Health Care raising money or cutting debt?
See what Zota Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Zota Health Care's order book?
2 more points from Zota Health Care Ltd's call on order book
Create a free account to keep reading this call
What the Q2 FY27 call signalled
2 of 3 strong
Zota Health Care Ltd — Quarterly revenue & net profit
Zota Health Care Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 199 | 129 | +54.3% | 174 | +14.4% |
| Operating profit (EBITDA) | 3 | 6 | -50% | -12 | — |
| Operating margin | 1.5% | 4.9% | -3.4 pp | -7% | +8.5 pp |
| Profit before tax | -27 | -14 | — | -44 | — |
| Net profit (PAT) | -26 | -16 | — | -44 | — |
| EPS (₹) | -7.39 | -5.20 | — | -12.58 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹199 Cr, net loss ₹26 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zota Health Care's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
Earlier calls (2)
Others in Pharmaceuticals & Biotechnology this season
- Divis Laboratories (Q2 FY27)
Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec
- Infinium Pharma (Q2 FY27)
3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto
- Walpar Nutrition (Q2 FY27)
3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zota Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zota Health Care Ltd Q2 FY27 results?
Davaindia sales grew by over 76% year-on-year in Q2FY27, indicating strong underlying momentum. Mature Davaindia stores show strong growth potential with monthly GMV reaching ₹8 lakh per store and potential to go up to ₹10-15 lakh in 2-3 years.
What is Zota Health Care Ltd share price analysis?
Zota Health Care Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹4,267 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Zota Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.